Abstract

REVIEW ON COMPUTATIONAL INSIGHTS OF NOVEL ANTICANCER AGENT EMRICASAN BY TRACING RIPK3 PATHWAY HASTENING NECROPTOSIS

Bodkhe Suvarna Pandurang* and Biradar Rutumbara Sangram

.

Abstract

Cancer is a group of diseases involving uncontrolled growth of abnormal cells anywhere in a body. These abnormal cells are termed cancer cells, malignant cells, or tumor cells. Cancer is the second leading cause of death globally, accounting for an estimated 19.3 million cases and 10 million cancer deaths in 2020. Even though the cases of cancers are increasing day by day, except cytotoxic, targeted, and hormonal drugs no other way of treatment has been successfully developed so far. So it is need to develop a novel anticancer drugs. Thus, the objective of this review is to provide an insight over the computational study of novel anticancer agent Emricasan by tracing RIPK3 pathway hastening necroptosis. The review also contains brief idea about necroptosis process and pathological aspects of cancer. Drug emricasan is a caspase 8 inhibitor so, this review includes the QSAR study & molecular docking score of ligand - receptor complex, Emricasan and TNFR1.

Keywords: Novel Anticancer Agent, Necroptosis, TNFR1, Caspase 8, Emricasan, Docking Score.